These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31393093)

  • 1. Double-conditioning regimen consisting of high-dose thiotepa and melphalan with autologous stem cell rescue for high-risk pediatric solid tumors: A second report.
    Okada K; Yamasaki K; Nitani C; Fujisaki H; Osugi Y; Hara J
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27953. PubMed ID: 31393093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
    Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S
    Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
    Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
    Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
    Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
    Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
    Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
    Grisariu S; Shapira MY; Or R; Avni B
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
    Avramova B; Jordanova M; Michailov G; Konstantinov D; Christosova I; Bobev D
    J BUON; 2006; 11(4):433-8. PubMed ID: 17309174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
    Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma.
    Kremens B; Gruhn B; Klingebiel T; Hasan C; Laws HJ; Koscielniak E; Hero B; Selle B; Niemeyer C; Finckenstein FG; Schulz A; Wawer A; Zintl F; Graf N
    Bone Marrow Transplant; 2002 Dec; 30(12):893-8. PubMed ID: 12476282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Y
    Voegeli M; Rondeau S; Berardi Vilei S; Lerch E; Wannesson L; Pabst T; Rentschler J; Bargetzi M; Jost L; Ketterer N; Bischof Delaloye A; Ghielmini M
    Hematol Oncol; 2017 Dec; 35(4):576-583. PubMed ID: 27677906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
    Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
    Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
    Pession A; Prete A; Locatelli F; Bella S; Melchionda F; Garaventa A; Burnelli R; Paolucci G
    Med Pediatr Oncol; 1999 Nov; 33(5):450-4. PubMed ID: 10531568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and Safety of Treosulfan, Melphalan, and Thiotepa-Based Megachemotherapy with Autologous or Allogeneic Stem Cell Transplantation in Heavily Pretreated Children with Relapsed or Refractory Neuroblastoma.
    Wawrzyniak-Dzierżek E; Gajek K; Rybka B; Ryczan-Krawczyk R; Węcławek-Tompol J; Raciborska A; Mielcarek-Siedziuk M; Frączkiewicz J; Salamonowicz M; Kałwak K; Rosa M; Ślęzak A; Ussowicz M
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1792-1797. PubMed ID: 31085306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
    Diaz MA; Vicent MG; Madero L
    Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Treatment of Refractory or Relapsed Hepatoblastoma With Autologous Hematopoietic Stem Cell Transplantation in Children.
    Kim BK; Choi JY; Hong KT; Park HJ; Kang HJ
    J Pediatr Hematol Oncol; 2024 Jul; 46(5):e265-e271. PubMed ID: 38830616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors.
    Chan KW; Petropoulos D; Choroszy M; Herzog C; Jaffe N; Ater J; Korbling M
    Bone Marrow Transplant; 1997 Dec; 20(12):1039-43. PubMed ID: 9466276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies.
    Gordillo CA; Parmar S; Blanco M; Delille EM; Assal A; Mapara M; Reshef R
    Ann Hematol; 2021 Jul; 100(7):1863-1870. PubMed ID: 33388856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in glomerular filtration rate and clinical course after sequential doses of carboplatin in children with embryonal brain tumors undergoing autologous stem cell transplantation.
    Elborai Y; Almutereen M; Maher OM; Hafez H; Lee MA; Lehmann L
    J Egypt Natl Canc Inst; 2020 Feb; 32(1):9. PubMed ID: 32372349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.